Of note, recent data from the European Tarceva (EURTAC) trial demonstrated poorer outcomes in EGFR-mutant NSCLC patients with low BIM expression, further supporting the importance of intact apoptotic machinery in such populations [21]. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.